GLP-1 Formula to boost GLP-1 and improve blood sugar control
Exploring the Effects of GLP-1 Formula on GLP-1 Secretion and Postprandial Glucose Regulation
NA · Chung Shan Medical University · NCT07082062
This will test whether a multi-ingredient GLP-1 dietary supplement can raise GLP-1 levels and improve blood sugar and insulin responses in adults with higher body fat.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | Chung Shan Medical University (other) |
| Locations | 1 site (Taichung) |
| Trial ID | NCT07082062 on ClinicalTrials.gov |
What this trial studies
This randomized, crossover investigation tests a multi-component oral GLP-1 Formula containing a probiotic (Bifidobacterium breve), a prebiotic blend (including kombucha extract, soy peptide, L‑arabinose, erythritol), and rocket apple extract for effects on incretin and glycemic responses. The study is split into two parallel crossover trials of about 50 participants each: one measuring acute changes in circulating GLP-1 after a single dose and the other measuring postprandial glucose and insulin responses. Participants attend two intervention visits per trial with at least a one-month washout if enrolled in both trials; each visit involves fasting and serial post-meal blood sampling over roughly six hours and appetite assessments. The trial enrolls healthy adults 18–50 years with body fat >25% and excludes people with diabetes, major GI disorders, recent probiotic or weight-loss supplement use, pregnancy, or prior GI surgery.
Who should consider this trial
Good fit: Adults 18–50 years old with body fat percentage over 25% who are not pregnant or breastfeeding and have no diabetes, major gastrointestinal disease, recent probiotic or weight-loss product use, or prior gastrointestinal surgery.
Not a fit: People with diabetes, autoimmune disease, chronic gastrointestinal disorders, prior gastrointestinal surgery, lactose intolerance, recent use of probiotics or weight-loss products, or who are pregnant or breastfeeding are excluded and unlikely to receive benefit from joining this trial.
Why it matters
Potential benefit: If successful, the formula could increase endogenous GLP-1 secretion and improve post-meal glucose and insulin control, potentially supporting metabolic health in overweight adults.
How similar studies have performed: Some prior studies of specific probiotics or prebiotics have shown modest effects on incretin hormones and postprandial glucose, but this exact multi-component GLP-1 Formula is novel and not widely tested in humans.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female participants aged 18-50 years with a body fat percentage greater than 25%. Exclusion Criteria: * Use of probiotics, weight loss products, or gastrointestinal health-related supplements or medications within the past month. * Presence of diabetes, autoimmune diseases, cancer, chronic gastrointestinal disorders, lactose intolerance, or chronic diarrhea. * History of gastrointestinal surgery. * Pregnant or breastfeeding women.
Where this trial is running
Taichung
- Chung Shan Medical University Hospital — Taichung, Taiwan (RECRUITING)
Study contacts
- Principal investigator: Shih-Chien Huang, PhD, Associate Professor — Chung Shan Medical University
- Study coordinator: Shih-Chien Huang, PhD, Associate Professor
- Email: schuang@csmu.edu.tw
- Phone: +886424730022
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Overweight, Probiotic, Prebiotic, Glucagon-like peptide-1, Blood glucose, Insulin